Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599759 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL9310069 | 0.89 | TK1 (0.60) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL3956430 | 0.88 | LMNA (0.51) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL3956427 | 0.88 | LMNA (0.51) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL10171803 | 0.82 | LMNA (0.55) | LMNATK1TSHRPMP22ADRA1A | |
| SCHEMBL9470674 | 0.82 | LMNA (0.55) | LMNATK1TSHRPMP22ADRA1A | |
| SCHEMBL9309488 | 0.81 | LMNA (0.53) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL22647744 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL9311378 | 0.78 | LMNA (0.62) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL10171991 | 0.78 | LMNA (0.47) | LMNASMN1; SMN2MAPTESR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1828145-A4 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | UNIV EMORY (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1828145-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
| WO-2006063281-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | LMNA 2156/4885SMN1; SMN2 1275/4885TK1 35/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | LMNA 2607/4885SMN1; SMN2 1385/4885TK1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.